It is important to note, though, that the development/refinement of the presently reviewed mitochondria-based therapeutics will require a multidisciplinary approach, including the identification of specific mitochondrial targets, a deeper understanding of how the tested substances affect the interactions between mitochondria and AD hallmarks (e.g., Aβ and tau) and consequently their toxicity, the optimization of drug delivery, and the development of new imaging techniques to monitor the effectiveness of the therapy in order achieve its full potential [319]. This evidence concerns the gene MAPT and Alzheimer disease.